NTUS · Natus Medical Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Revenue | $473.44M | $415.68M | $495.18M | $530.89M | $500.97M | $381.89M |
| Cost of Revenue | - | - | $196.55M | $144.63M | $213.38M | $144.63M |
| Gross Profit | $273.68M | $216.53M | $291.71M | $304.01M | $281.21M | $234.93M |
| R&D | $56.31M | $61.30M | $58.73M | $61.48M | $51.82M | $33.44M |
| SG&A | $52.75M | $49.11M | $59.65M | $70.60M | $74.42M | $50.88M |
| Total Operating Expenses | $249.90M | $236.72M | $307.37M | $328.58M | $272.50M | $179.67M |
| D&A | $28.09M | $28.11M | $30.72M | $33.86M | $30.10M | $16.88M |
| Operating Income | $23.78M | ($20.19M) | ($15.67M) | ($24.56M) | $8.72M | $55.26M |
| Interest Expense | $1.87M | $3.66M | $4.94M | $6.79M | $5.08M | $430.0K |
| Income Tax | $6.18M | ($5.45M) | ($5.59M) | ($9.32M) | $25.44M | $12.31M |
| Net Income | $13.18M | ($16.61M) | ($15.67M) | ($22.93M) | ($20.29M) | $42.59M |
| EPS - Basic | $0.39 | ($0.49) | ($0.47) | ($0.69) | ($0.62) | $1.31 |
| EPS - Diluted | $0.39 | ($0.49) | ($0.47) | ($0.69) | ($0.62) | $1.29 |
Balance Sheet
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $75.59M | $82.08M | $63.30M | $56.37M | $88.95M | $213.55M |
| Accounts Receivable | $111.76M | $93.13M | $115.89M | $127.04M | $126.81M | $86.64M |
| Inventory | $67.75M | $75.65M | $71.37M | $79.74M | $71.53M | $49.59M |
| Accounts Payable | $36.41M | $23.43M | $27.25M | $28.80M | $25.24M | $18.70M |
| Current Assets | $277.29M | $271.70M | $269.75M | $285.77M | $305.63M | $405.80M |
| Total Assets | $564.29M | $600.39M | $622.53M | $638.14M | $709.92M | $649.01M |
| Current Liabilities | $114.60M | $145.75M | $142.82M | $133.45M | $92.14M | $79.94M |
| Long-term Debt | $0 | $5.84M | $19.66M | $69.47M | $154.28M | $140.00M |
| Total Liabilities | $139.54M | $189.30M | $206.40M | $239.70M | $287.82M | $231.64M |
| Stockholders' Equity | $424.75M | $411.09M | $416.12M | $398.44M | $422.10M | $417.37M |
| Retained Earnings | $84.49M | $71.31M | $87.92M | $102.26M | $129.12M | $149.41M |
Cash Flow
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $63.99M | $34.43M | $60.06M | $33.02M | $19.73M | $72.69M |
| Investing Cash Flow | ($1.95M) | ($12.61M) | ($5.34M) | ($8.39M) | ($160.94M) | ($53.26M) |
| Financing Cash Flow | ($60.66M) | ($10.88M) | ($48.53M) | ($49.51M) | $5.83M | $118.42M |
| CapEx | $3.62M | $8.61M | $5.33M | $7.88M | $4.07M | $3.19M |
| Free Cash Flow | $60.38M | $25.82M | $54.73M | $25.14M | $15.66M | $69.50M |
Ratios
| Metric | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 57.8% | 52.1% | 58.9% | 57.3% | 56.1% | 61.5% |
| Operating margin | 5.0% | -4.9% | -3.2% | -4.6% | 1.7% | 14.5% |
| EBITDA margin | 11.0% | 1.9% | 3.0% | 1.8% | 7.7% | 18.9% |
| Net margin | 2.8% | -4.0% | -3.2% | -4.3% | -4.1% | 11.2% |
| Free cash flow margin | 12.8% | 6.2% | 11.1% | 4.7% | 3.1% | 18.2% |
| FCF / Net income | 4.58 | -1.55 | -3.49 | -1.10 | -0.77 | 1.63 |
| R&D / Revenue | 11.9% | 14.7% | 11.9% | 11.6% | 10.3% | 8.8% |
| SG&A / Revenue | 11.1% | 11.8% | 12.0% | 13.3% | 14.9% | 13.3% |
| Effective tax rate | 31.9% | - | - | - | 494.0% | 22.4% |
| Return on assets | 2.3% | -2.8% | -2.5% | -3.6% | -2.9% | 6.6% |
| Return on equity | 3.1% | -4.0% | -3.8% | -5.8% | -4.8% | 10.2% |
| Return on invested capital | 3.8% | -3.8% | -2.8% | -4.1% | 0.8% | 7.7% |
| Liquidity | ||||||
| Current ratio | 2.42 | 1.86 | 1.89 | 2.14 | 3.32 | 5.08 |
| Quick ratio | 1.83 | 1.35 | 1.39 | 1.54 | 2.54 | 4.46 |
| Cash ratio | 0.66 | 0.56 | 0.44 | 0.42 | 0.97 | 2.67 |
| Leverage | ||||||
| Debt / Equity | 0.00 | 0.01 | 0.05 | 0.17 | 0.37 | 0.34 |
| Debt / Assets | 0.00 | 0.01 | 0.03 | 0.11 | 0.22 | 0.22 |
| Debt / EBITDA | 0.00 | 0.74 | 1.31 | 7.47 | 3.97 | 1.94 |
| Interest coverage | 12.7x | -5.5x | -3.2x | -3.6x | 1.7x | 128.5x |
| Equity multiplier | 1.33 | 1.46 | 1.50 | 1.60 | 1.68 | 1.55 |
| Liabilities / Assets | 0.25 | 0.32 | 0.33 | 0.38 | 0.41 | 0.36 |
| Efficiency | ||||||
| Asset turnover | 0.84 | 0.69 | 0.80 | 0.83 | 0.71 | 0.59 |
| Inventory turnover | - | - | 2.75 | 1.81 | 2.98 | 2.92 |
| Days sales outstanding | 86d | 82d | 85d | 87d | 92d | 83d |
| Days inventory outstanding | - | - | 133d | 201d | 122d | 125d |
| Days payable outstanding | - | - | 51d | 73d | 43d | 47d |
| Cash conversion cycle | - | - | 167d | 216d | 172d | 161d |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 13.9% | -16.1% | -6.7% | 6.0% | 31.2% | 1.6% |
| Revenue CAGR (3y) | -3.7% | -6.0% | 9.0% | 12.2% | 12.1% | 3.5% |
| Revenue CAGR (5y) | 4.4% | 2.0% | 6.8% | 9.1% | 11.4% | 18.1% |
| Gross profit growth (YoY) | 26.4% | -25.8% | -4.0% | 8.1% | 19.7% | 3.3% |
| Operating income growth (YoY) | - | -28.9% | 36.2% | - | -84.2% | 3.3% |
| Net income growth (YoY) | - | -6.0% | 31.7% | -13.0% | - | 12.3% |
| EPS growth (YoY) | - | -4.3% | 31.9% | -11.3% | - | 13.2% |
| EPS CAGR (3y) | - | - | - | - | - | 20.4% |
| EPS CAGR (5y) | -21.3% | - | - | - | - | 26.4% |
| FCF growth (YoY) | 133.9% | -52.8% | 117.7% | 60.6% | -77.5% | 112.0% |
| FCF CAGR (5y) | -2.8% | -4.7% | 7.6% | -6.4% | 5.4% | 23.7% |
| Book value growth (YoY) | 3.3% | -1.2% | 4.4% | -5.6% | 1.1% | 6.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Business segments
$473.44M totalNeurology Products$284.77M · 60.1%
Newborn Care Products$105.02M · 22.2%
Otometrics Products$83.65M · 17.7%
Product / service
$300.91M totalDevices And Systems$220.93M · 73.4%
Supplies$63.84M · 21.2%
Services$16.14M · 5.4%
Geographic
$473.44M totalUS$285.98M · 60.4%
Non Us$187.46M · 39.6%
Stability scores
Altman Z′
FY 2021 · bankruptcy risk
2.58
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2021 · 9-point quality
8/9
Strong
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Electromedical & Electrotherapeutic Apparatus
Comparing NATUS MEDICAL INC against the 5 most active filers in the same SIC group.